Selected Articles from This Issue

Patients with HR⁺/HER2⁺ breast cancer often experience metastasis to the viscera or central nervous system (CNS) and diminished response to HR and HER2 targeted therapies, due in part to cyclin D1/CDK4/6 signaling and leading to high mortality rates. Current chemotherapeutic regimens are accompanied by unwanted side effects, and thus alternative therapeutic strategies targeting HER2 and hormone receptor signaling pathways that maximize efficacy while minimizing adverse events (AEs) are needed. In this phase Ib/II clinical trial, Shagisultanova and colleagues assess the safety and efficacy of the HER2 inhibitor tucatinib in combination with the aromatase inhibitor letrozole and the CDK4/6 inhibitor palbociclib (TLP) in HR⁺/HER2⁺ metastatic breast cancer patients. The phase II dose was well tolerated with manageable grade ≥ 3 AEs. The authors report an overall median progression free survival (mPFS) of 8.4 months, with a mPFS of 10.0 months in patients without CNS metastases...